EBS Share Price

Open 30.31 Change Price %
High 30.61 1 Day -0.05 -0.16
Low 30.06 1 Week 1.74 6.09
Close 30.31 1 Month 1.47 5.10
Volume 171401 1 Year -8.89 -22.68
52 Week High 44.38
52 Week Low 24.47
EBS Important Levels
Resistance 2 30.82
Resistance 1 30.61
Pivot 30.33
Support 1 30.01
Support 2 29.80
NYSE USA Most Active Stocks
EMC 29.05 0.97%
EMC 29.05 0.97%
EMC 29.05 0.97%
SE 40.68 -0.78%
PCS 11.84 -0.92%
PCS 11.84 -0.92%
PCS 11.84 -0.92%
BAC 23.65 -1.00%
BAC 23.65 -1.00%
BAC 23.65 -1.00%
More..
NYSE USA Top Gainers Stocks
POM 26.93 26.79%
POM 26.93 26.79%
GLF 0.34 25.93%
GLF 0.34 25.93%
FNP 35.24 12.02%
FNP 35.24 12.02%
MTL 5.76 11.63%
MTL 5.76 11.63%
CVI 21.96 11.53%
HF 31.88 11.51%
More..
NYSE USA Top Losers Stocks
ENL 15.81 -66.25%
ENL 15.81 -66.25%
ENL 15.81 -66.25%
MHR 0.15 -42.31%
MHR 0.15 -42.31%
MHR 0.15 -42.31%
STP 0.53 -39.77%
STP 0.53 -39.77%
STP 0.53 -39.77%
STP 0.53 -39.77%
More..

Emergent Biosolutions, Inc. (NYSE: EBS)

EBS Technical Analysis 1.5
As on 27th Apr 2017 EBS Share Price closed @ 30.31 and we RECOMMEND Sell for LONG-TERM with Stoploss of 30.74 & Buy for SHORT-TERM with Stoploss of 29.78 we also expect STOCK to react on Following IMPORTANT LEVELS.
EBS Target for April
1st Target up-side 31.39
2nd Target up-side 33.04
3rd Target up-side 34.68
1st Target down-side 26.69
2nd Target down-side 25.04
3rd Target down-side 23.4
EBS Other Details
Segment EQ
Market Capital 529524064.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.emergentbiosolutions.com
EBS Address
EBS
2273 Research Boulevard
Suite 400
Rockville, MD 20850
United States
Phone: 301-795-1800
Fax: 301-795-1899
EBS Latest News
Emergent Biosolutions Inc (EBS) Shares Bought by Teachers Advisors LLC   The Cerbat Gem   - 25th Apr 17
Emergent BioSolutions gets $100 million anthrax contract from feds   Washington Business Journal   - 20th Mar 17
Emergent BioSolutions Inc Sets Its Goal   Motley Fool   - 25th Feb 17
Why Emergent Biosolutions Inc. Stockpiled a Higher Price Today   Motley Fool   - 10th Dec 16
Emergent Biosolutions Inc Slimmed Down, Waiting on Contract   Motley Fool   - 11th Nov 16
Why Emergent Biosolutions Inc Surged Higher Today   Motley Fool   - 01st Oct 16
Emergent BioSolutions Inc. Asks for Patience   Motley Fool   - 11th Aug 16
Emergent BioSolutions Is Oversold   Forbes   - 27th Jun 16
Why Emergent BioSolutions Inc. Procured a Lower Price Today   Motley Fool   - 23rd Jun 16
Emergent BioSolutions Inc in Transition   Motley Fool   - 13th May 16
Interactive Technical Analysis Chart Emergent Biosolutions, Inc. ( EBS NYSE USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Emergent Biosolutions, Inc.
EBS Business Profile
Emergent BioSolutions Inc., a specialty pharmaceutical company, develops, manufactures, and commercializes specialized products for use in defense and commercial markets in the United States and internationally. The company operates in two segments, Biodefense and Biosciences. The Biodefense segment markets BioThrax, an FDA approved vaccine for the prevention of anthrax disease; BAT (Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-Equine) for the treatment of suspected or documented exposure to botulinum neurotoxin A, B, C, D, E, F, or G; Vaccinia Immune Globulin Intravenous for counteracting complications associated with the smallpox vaccine; and RSDL (decontamination lotion) to remove and/or neutralize chemical warfare agents from the skin. This segment is also developing Anthrax Immune Globulin Intravenous to treat toxemia associated with inhalational anthrax; NuThrax, an anthrax vaccine in Phase II clinical trials, which is based on BioThrax combined with CPG 7909, an adjuvant licensed from Pfizer Inc.; and PreviThrax, a recombinant protective antigen anthrax vaccine product candidate. The Biosciences segment markets WinRho SDF, to treat immune thrombocytopenic purpura, an autoimmune platelet disorder; HepaGam B for the prevention of Hepatitis B reinfection after liver transplantation, and for use as a post-exposure prophylaxis; VARIZIG for post-exposure prophylaxis of chickenpox; and Episil to treat pain associated with oral mucositis. It is also developing Otlertuzumab, a mono-specific protein therapeutic in Phase II clinical trials for the treatment of chronic lymphocytic leukemia; and IXINITY, a therapeutic to prevent bleeding episodes in people with hemophilia B. In addition, this segment provides contract manufacturing services to third-party customers. Emergent BioSolutions Inc. was founded in 1998 and is based in Rockville, Maryland.